A newreagent, tetrabutylammonium pyridin-2-olate, was prepared and its application to the efficient synthesis of N-aryl pyridine-2-ones was demonstrated using CuI-catalyzed coupling reactions with aryl iodides. This coupling reaction is mild, high-yielding, and remarkably chemoselective (N- vs. O-arylation). It is also compatible with substrates containing labile functional groups.
制备了一种新试剂 吡啶-2-醇四丁基铵,并通过 CuI 催化与芳基碘化物的偶联反应证明了其在高效合成 N-芳基吡啶-2-酮中的应用。这种偶联反应温和、高产且具有显着的化学选择性(N- 与 O-芳基化)。它还与含有不稳定官能团的底物相容。
DICARBOXAMIDE DERIVATIVES
申请人:Boehringer Markus
公开号:US20090270360A1
公开(公告)日:2009-10-29
The invention is concerned with novel dicarboxamide derivatives of formula (I)
wherein A, B, R
c
, D and E are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
申请人:Kalvista Pharmaceuticals Limited
公开号:US10781181B2
公开(公告)日:2020-09-22
The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, U, D, E, W, X, Y and Z are as defined herein.
本发明提供了式(I)化合物:(I)包含此类化合物的组合物;此类化合物在治疗中的用途(例如在治疗或预防涉及血浆卡利克瑞因活性的疾病或病症中的用途);以及用此类化合物治疗患者的方法;其中 R5、R6、R7、A、B、U、D、E、W、X、Y 和 Z 如本文所定义。
N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS
申请人:KALVISTA PHARMACEUTICALS LIMITED
公开号:US20170305863A1
公开(公告)日:2017-10-26
The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, U, D, E, W, X, Y and Z are as defined herein.